Search Results - "Senzer, Neil N"

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma by SENZER, Neil N, KAUFMAN, Howard L, GOLDSWEIG, Howard, MARSHALL, Tracey, LOVE, Colin, COFFIN, Robert, NEMUNAITIS, John J, AMATRUDA, Thomas, NEMUNAITIS, Mike, REID, Tony, DANIELS, Gregory, GONZALEZ, Rene, GLASPY, John, WHITMAN, Eric, HARRINGTON, Kevin

“…Treatment options for metastatic melanoma are limited. We conducted this phase II trial to assess the efficacy of JS1/34.5-/47-/granulocyte-macrophage…”
Get full text

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer by SEQUIST, Lecia V, GETTINGER, Scott, SWEENEY, Jennifer, WALKER, John R, FRITZ, Christian, ROSS, Robert W, GRAYZEL, David, ENGELMAN, Jeffrey A, BORGER, Darrell R, PAEZ, Guillermo, NATALE, Ronald, SENZER, Neil N, MARTINS, Renato G, JÄNNE, Pasi A, LILENBAUM, Rogerio, GRAY, Jhanelle E, IAFRATE, A. John, KATAYAMA, Ryohei, HAFEEZ, Nafeeza

“…IPI-504 is a novel, water-soluble, potent inhibitor of heat-shock protein 90 (Hsp90). Its potential anticancer activity has been validated in preclinical in…”
Get full text

Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck by SOULIERES, Denis, SENZER, Neil N, VOKES, Everett E, HIDALGO, Manuel, AGARWALA, Sanjiv S, SIU, Lillian L

“…To determine the efficacy and safety profiles of erlotinib in patients with advanced recurrent and/or metastatic squamous cell cancer of the head and neck…”
Get full text

Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma by Eager, Robert M, Cunningham, C Casey, Senzer, Neil N, Stephenson, Jr, Joe, Anthony, Stephen P, O'Day, Steven J, Frenette, Gary, Pavlick, Anna C, Jones, Barry, Uprichard, Margaret, Nemunaitis, John

“…Metastatic melanoma is an incurable disease with an average survival of less than one year. Talabostat is a novel dipeptidyl peptidase inhibitor with…”
Get full text

Phase III Multicenter Trial of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel Compared With Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel As Adjuvant Therapy for Women With High-Risk Breast Cancer by LOESCH, David, GRECO, F. Anthony, PIPPEN, John, LINDQUIST, Deborah, MCINTYRE, Kristi, BLUM, Joanne L, MODIANO, Manuel R, BOEHM, Kristi A, FENG ZHAN, ASMAR, Lina, ROBERT, Nicholas, SENZER, Neil N, BURRIS, Howard A, HAINSWORTH, John D, JONES, Stephen, VUKELJA, Svetislava J, SANDBACH, John, HOLMES, Frankie, SEDLACEK, Scot

“…This study compared disease-free survival (DFS) obtained with two different regimens of adjuvant therapy in high-risk breast cancer. Women (who had performance…”
Get full text

Phase I Clinical Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features by RUDIN, Charles M, POIRIER, John T, SENZE, Neil N, STEPHENSON, Joseph, LOESCH, David, BURROUGHS, Kevin D, SESHIDHAR REDDY, P, HANN, Christine L, HALLENBECK, Paul L

“…Seneca Valley Virus (SVV-001) is a novel naturally occurring replication-competent picornavirus with potent and selective tropism for neuroendocrine cancer…”
Get full text

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study by Kaufman, Howard L, Amatruda, Thomas, Reid, Tony, Gonzalez, Rene, Glaspy, John, Whitman, Eric, Harrington, Kevin, Nemunaitis, John, Zloza, Andrew, Wolf, Michael, Senzer, Neil N

“…We previously reported that talimogene laherparepvec, an oncolytic herpes virus encoding granulocyte-macrophage colony-stimulating factor (GM-CSF), resulted in…”
Get full text

Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors by Mahalingam, Devalingam, Nemunaitis, John J., Malik, Laeeq, Sarantopoulos, John, Weitman, Steven, Sankhala, Kamalesh, Hart, Jessica, Kousba, Ahmed, Gallegos, Nicole S., Anderson, Gavin, Charles, John, Rogers, Jon M., Senzer, Neil N., Mita, Alain C.

“…Purpose ATI-1123 is a liposomal formulation of docetaxel and may be administered without the premedications and hypersensitivity reactions. This Phase I study…”
Get full text

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma by Jamieson, Stephen Mf, Tsai, Peter, Kondratyev, Maria K, Budhani, Pratha, Liu, Arthur, Senzer, Neil N, Chiorean, E Gabriela, Jalal, Shadia I, Nemunaitis, John J, Kee, Dennis, Shome, Avik, Wong, Way W, Li, Dan, Poonawala-Lohani, Nooriyah, Kakadia, Purvi M, Knowlton, Nicholas S, Lynch, Courtney Rh, Hong, Cho R, Lee, Tet Woo, Grénman, Reidar A, Caporiccio, Laura, McKee, Trevor D, Zaidi, Mark, Butt, Sehrish, Macann, Andrew Mj, McIvor, Nicholas P, Chaplin, John M, Hicks, Kevin O, Bohlander, Stefan K, Wouters, Bradly G, Hart, Charles P, Print, Cristin G, Wilson, William R, Curran, Michael A, Hunter, Francis W

“…Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus…”
Get full text

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy by Shen, Yuqiao, Senzer, Neil N., Nemunaitis, John J.

“…Abstract non disponibile…”
Get full text

Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma by Goyal, Lipika, Supko, Jeffrey G, Berlin, Jordan, Blaszkowsky, Lawrence S, Carpenter, Amanda, Heuman, Douglas M, Hilderbrand, Sarah L, Stuart, Keith E, Cotler, Scott, Senzer, Neil N, Chan, Emily, Berg, Carl L, Clark, Jeffrey W, Hezel, Aram F, Ryan, David P, Zhu, Andrew X

“…N(1),N(11)-diethylnorspermine (DENSPM), a synthetic analog of the naturally occurring polyamine spermine, can induce polyamine depletion and inhibit tumor cell…”
Get full text

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma by Jamieson, Stephen Mf, Tsai, Peter, Kondratyev, Maria K, Budhani, Pratha, Liu, Arthur, Senzer, Neil N, Chiorean, E Gabriela, Jalal, Shadia I, Nemunaitis, John J, Kee, Dennis, Shome, Avik, Wong, Way W, Li, Dan, Poonawala-Lohani, Nooriyah, Kakadia, Purvi M, Knowlton, Nicholas S, Lynch, Courtney Rh, Hong, Cho R, Lee, Tet Woo, Grénman, Reidar A, Caporiccio, Laura, McKee, Trevor D, Zaidi, Mark, Butt, Sehrish, Macann, Andrew Mj, McIvor, Nicholas P, Chaplin, John M, Hicks, Kevin O, Bohlander, Stefan K, Wouters, Bradly G, Hart, Charles P, Print, Cristin G, Wilson, William R, Curran, Michael A, Hunter, Francis W

Get full text

Phase I dose-escalation study of talimogene laherparepvec (T-VEC) for advanced pancreatic cancer (ca) by Chang, Kenneth J., Senzer, Neil N., Binmoeller, Kenneth, Goldsweig, Howard, Coffin, Robert

“…Abstract only e14546 Background: T-VEC is an investigational, immune-enhanced oncolytic herpes simplex virus type I that selectively replicates in solid…”
Get full text

Primary overall survival (OS) from OPTiM, a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma by Kaufman, Howard L, Andtbacka, Robert Hans Ingemar, Collichio, Frances A., Amatruda, Thomas, Senzer, Neil N., Chesney, Jason, Delman, Keith A., Spitler, Lynn E., Puzanov, Igor, Ye, Yining, Li, Ai, Gansert, Jennifer L., Coffin, Robert, Ross, Merrick I.

“…Abstract only…”
Get full text

Phase I trial of irinotecan, infusional 5-fluorouracil, and leucovorin (FOLFIRI) with erlotinib (OSI-774): Early termination due to increased toxicities by MESSERSMITH, Wells A, LAHERU, Daniel A, SENZER, Neil N, DONEHOWER, Ross C, GROULEFF, Paula, ROGERS, Theresa, KELLEY, Sean K, RAMIES, David A, LUM, Bert L, HIDALGO, Manuel

“…This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor receptor…”
Get full text

OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma by Andtbacka, Robert Hans Ingemar, Collichio, Frances A., Amatruda, Thomas, Senzer, Neil N., Chesney, Jason, Delman, Keith A., Spitler, Lynn E., Puzanov, Igor, Doleman, Susan, Ye, Yining, Vanderwalde, Ari M., Coffin, Robert, Kaufman, Howard

“…Abstract only LBA9008 Background: T-VEC is an oncolytic immunotherapy (OI) derived from herpes simplex virus type-1 designed to selectively replicate within…”
Get full text

Phase 1 study of N1,N11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma by Goyal, Lipika, Supko, Jeffrey G., Berlin, Jordan, Blaszkowsky, Lawrence S., Carpenter, Amanda, Heuman, Douglas M., Hilderbrand, Sarah L., Stuart, Keith E., Cotler, Scott, Senzer, Neil N., Chan, Emily, Berg, Carl L., Clark, Jeffrey W., Hezel, Aram F., Ryan, David P., Zhu, Andrew X.

“…Purpose N 1 , N 11 -diethylnorspermine (DENSPM), a synthetic analog of the naturally occurring polyamine spermine, can induce polyamine depletion and inhibit…”
Get full text

Use of Proteomics Analysis for Molecular Precision Approaches in Cancer Therapy by Shen, Yuqiao, Senzer, Neil N., Nemunaitis, John J.

“…Yuqiao Shen1, Neil N. Senzer1,2 and John J. Nemunaitis2 1LEAD Therapeutics, Inc., San Bruno, CA. 2Mary Crowley Cancer Research Centers, Dallas, TX. Abstract…”
Get full text

Chemoinducible gene therapy by Mezhir, James J, Schmidt, Hank, Yamini, Bakhtiar, Senzer, Neil N, Posner, Mitchell C, Kufe, Donald W, Weichselbaum, Ralph R

“…Chemoinducible cancer gene therapy is a potential new treatment for solid tumors that may in part enhance the anti-tumor effects of chemotherapy while…”
Get full text

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) by Messersmith, Wells A., Laheru, Daniel A., Senzer, Neil N., Donehower, Ross C., Grouleff, Paula, Rogers, Theresa, Kelley, Sean K., Ramies, David A., Lum, Bert L., Hidalgo, Manuel

“…Purpose: This phase I study was conducted to establish the dose-limiting toxicities and maximum-tolerated dose of erlotinib, an oral epidermal growth factor…”
Get full text